178 related articles for article (PubMed ID: 15202167)
1. A fetal case of transient abnormal myelopoiesis with severe liver failure in Down syndrome: prognostic value of serum markers.
Shiozawa Y; Fujita H; Fujimura J; Suzuki K; Sato H; Saito M; Shimizu T; Yamashiro Y
Pediatr Hematol Oncol; 2004; 21(3):273-8. PubMed ID: 15202167
[TBL] [Abstract][Full Text] [Related]
2. [Prognostic value of serum markers for liver fibrosis in transient abnormal myelopoiesis (TAM)].
Kuroiwa Y; Suzuki N; Yamamoto M; Hatakeyama N; Hori T; Mizue N
Rinsho Ketsueki; 2005 Nov; 46(11):1179-86. PubMed ID: 16440800
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of serum hepatic fibrosis markers in the diagnosis of nonalcoholic steatohepatitis (NASH).
Sasaki N; Ueno T; Morita Y; Nagata E; Sata M
Hepatogastroenterology; 2006; 53(71):678-81. PubMed ID: 17086867
[TBL] [Abstract][Full Text] [Related]
4. Serum markers of liver fibrosis and histologic severity of fibrosis in resected liver.
Tsukamoto T; Yamamoto T; Ikebe T; Takemura S; Shuto T; Kubo S; Hirohashi K; Kinoshita H
Hepatogastroenterology; 2004; 51(57):777-80. PubMed ID: 15143915
[TBL] [Abstract][Full Text] [Related]
5. Transient abnormal myelopoiesis associated with Down syndrome presenting as severe hydrops fetalis: a case report.
Malin GL; Kilby MD; Velangi M
Fetal Diagn Ther; 2010; 27(3):171-3. PubMed ID: 20160425
[TBL] [Abstract][Full Text] [Related]
6. Improving circulatory disturbance in transient abnormal myelopoiesis.
Koga H; Miyako K; Suga N; Hidaka T; Takahashi N
J Pediatr Hematol Oncol; 2012 May; 34(4):e149-51. PubMed ID: 22134612
[TBL] [Abstract][Full Text] [Related]
7. [Unusual hepatic fibrosis in three cases of Down syndrome].
Inoue T; Kobayashi Y; Kusuda S
Rinsho Byori; 1996 Jun; 44(6):590-4. PubMed ID: 8752740
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin.
Trocme C; Leroy V; Sturm N; Hilleret MN; Bottari S; Morel F; Zarski JP
J Viral Hepat; 2006 Oct; 13(10):643-51. PubMed ID: 16970595
[TBL] [Abstract][Full Text] [Related]
9. [Transitory abnormal myelopoiesis of the monoblastic form in a newborn infant with Down's syndrome and liver cirrhosis].
Urano Y; Kondo M; Hayashi Y; Wakuya J; Nakata T; Tanaka K; Seo A
Ann Pathol; 1983 Dec; 3(4):337-9. PubMed ID: 6230084
[TBL] [Abstract][Full Text] [Related]
10. Transient abnormal myelopoiesis (TAM) causing multiple organ failure.
Hoskote A; Chessells J; Pierce C
Intensive Care Med; 2002 Jun; 28(6):758-62. PubMed ID: 12107683
[TBL] [Abstract][Full Text] [Related]
11. Value of fibrosis markers for staging liver fibrosis in patients with precirrhotic alcoholic liver disease.
Lieber CS; Weiss DG; Paronetto F;
Alcohol Clin Exp Res; 2008 Jun; 32(6):1031-9. PubMed ID: 18422837
[TBL] [Abstract][Full Text] [Related]
12. Resolution of liver disease in transient abnormal myelopoiesis with fish oil emulsion.
Watanabe T; Amari S; Tsukamoto K; Ito Y; Tomizawa D; Yoshioka T; Kanamori Y
Pediatr Int; 2017 Apr; 59(4):515-518. PubMed ID: 28401746
[TBL] [Abstract][Full Text] [Related]
13. [Clinical and pathological study on liver fibrosis in viral hepatitis].
Xin S; Mao Y; Wang L; Li Y; Li L; Yu H; Zhao M; Zhang S; Wang S; Wang X; Chen L; Zhou X; Zhou Y; Zou Z; Tang S; Huangpu Y; Zhang L
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Sep; 11(3):240-3. PubMed ID: 15617338
[TBL] [Abstract][Full Text] [Related]
14. Collagen IV is a predictor for clinical course in patients with malignant obstructive jaundice.
Mizuguchi Y; Yoshida H; Yokomuro S; Arima Y; Mamada Y; Taniai N; Akimaru K; Tajiri T
Hepatogastroenterology; 2005; 52(63):672-7. PubMed ID: 15966179
[TBL] [Abstract][Full Text] [Related]
15. Serum markers of hepatic fibrogenesis in cystic fibrosis liver disease.
Pereira TN; Lewindon PJ; Smith JL; Murphy TL; Lincoln DJ; Shepherd RW; Ramm GA
J Hepatol; 2004 Oct; 41(4):576-83. PubMed ID: 15464237
[TBL] [Abstract][Full Text] [Related]
16. Life-threatening complications of transient abnormal myelopoiesis in neonates with Down syndrome.
Dormann S; Krüger M; Hentschel R; Rasenack R; Strahm B; Kontny U; Niemeyer C
Eur J Pediatr; 2004 Jul; 163(7):374-7. PubMed ID: 15138809
[TBL] [Abstract][Full Text] [Related]
17. [Serum markers of liver fibrosis].
Schuppan D; Jax C; Hahn EG
Dtsch Med Wochenschr; 1999 Oct; 124(41):1213-8. PubMed ID: 10572522
[No Abstract] [Full Text] [Related]
18. Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen.
Maurice PD; Maddox AJ; Green CA; Tatnall F; Schofield JK; Stott DJ
Br J Dermatol; 2005 Mar; 152(3):451-8. PubMed ID: 15787813
[TBL] [Abstract][Full Text] [Related]
19. Chemokine levels predict progressive liver disease in Down syndrome patients with transient abnormal myelopoiesis.
Kinjo T; Inoue H; Kusuda T; Fujiyoshi J; Ochiai M; Takahata Y; Honjo S; Koga Y; Hara T; Ohga S
Pediatr Neonatol; 2019 Aug; 60(4):382-388. PubMed ID: 30314728
[TBL] [Abstract][Full Text] [Related]
20. Transient abnormal myelopoeisis in newborns with Down syndrome.
Zarina AL; Hamidah A; Yong SC; Rohana J; Hamidah NH; Azma RZ; Boo NY; Jamal R
Malays J Pathol; 2007 Dec; 29(2):107-11. PubMed ID: 19108403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
